Skip to main content

SARS-CoV-2 Virus Infection

3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Valneva
ValnevaAustria - Vienna
3 programs
1
2
VLA2001Phase 31 trial
VLA2001Phase 31 trial
VLA2001Phase 1/21 trial
Active Trials
NCT04671017Completed153Est. Apr 2022
NCT04956224Completed306Est. Nov 2022
NCT04864561Completed4,034Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ValnevaVLA2001
ValnevaVLA2001
ValnevaVLA2001

Clinical Trials (3)

Total enrollment: 4,493 patients across 3 trials

NCT04956224ValnevaVLA2001

Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years

Start: Aug 2021Est. completion: Nov 2022306 patients
Phase 3Completed
NCT04864561ValnevaVLA2001

COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222

Start: Apr 2021Est. completion: Mar 20234,034 patients
Phase 3Completed
NCT04671017ValnevaVLA2001

Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects

Start: Dec 2020Est. completion: Apr 2022153 patients
Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.